| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Control Delivery Systems Bausch & Lomb, Inc. |
| Information provided by: | Control Delivery Systems |
| ClinicalTrials.gov Identifier: | NCT00032396 |
Purpose
A study evaluating Retisert in patients with age-related macular degeneration
| Condition | Intervention | Phase |
|
Macular Degeneration |
Drug: Retisert Implant |
Phase II |
| Genetics Home Reference related topics: | X-linked juvenile retinoschisis |
| MedlinePlus related topics: | Macular Degeneration |
| ChemIDplus related topics: | Fluocinolone Fluocinolone acetonide |
| Study Type: | Interventional |
| Study Design: | Treatment |
Eligibility
| Ages Eligible for Study: | 55 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations More Information
Control Delivery Systems, Inc. Homepage
|
|
Information for Patients on AMD
|
| Study ID Numbers: | CDS FL-004 |
| First Received: | March 20, 2002 |
| Last Updated: | May 25, 2006 |
| ClinicalTrials.gov Identifier: | NCT00032396 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
